Diagnostics
Gate teams up with Beacon to use EEG biomarkers in Phase II MDD trial
Phase II of Gate’s zelquistinel will use Becon’s Dreem 3S headband device to conduct exploratory EEG and sleep analyses in patients with major depressive disorder.
Phase II of Gate’s zelquistinel will use Becon’s Dreem 3S headband device to conduct exploratory EEG and sleep analyses in patients with major depressive disorder.